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Oncocytomas are predominantly benign neoplasms
possessing pathogenic mitochondrial mutations
and accumulation of respiration-defective mitochon-
dria, characteristics of unknown significance. Using
exome and transcriptome sequencing, we identified
two main subtypes of renal oncocytoma. Type 1 is
diploid with CCND1 rearrangements, whereas type
2 is aneuploid with recurrent loss of chromosome 1,
X or Y, and/or 14 and 21, which may proceed to
more aggressive eosinophilic chromophobe renal
cell carcinoma (ChRCC). Oncocytomas activate 50
adenosine monophosphate-activated protein kinase
(AMPK) and Tp53 (p53) and display disruption of
Golgi and autophagy/lysosome trafficking, events
attributed to defective mitochondrial function. This
suggests that the genetic defects in mitochondria
activate a metabolic checkpoint, producing auto-
phagy impairment and mitochondrial accumulation
that limit tumor progression, revealing a novel tu-
mor-suppressive mechanism for mitochondrial inhi-
bition with metformin. Alleviation of this metabolic
checkpoint in type 2 by p53mutationsmay allow pro-
gression to eosinophilic ChRCC, indicating that they
represent higher risk.INTRODUCTION
Altered metabolism in cancer that promotes the fermentation of
glucose was proposed more than 50 years ago by Otto Warburg
to originate from respiratory system damage (Warburg, 1956).
Only recently with the discovery of cancer driver mutations in
nuclear genes encoding mitochondrial tricarboxylic acid (TCA)Cell Recycle enzymes have we begun to unravel the underlying onco-
genic functions linked to altered metabolism (Ward and Thomp-
son, 2012). Moreover, it is now clear that many oncogenic events
common in cancer indirectly regulate cellular metabolism (Van-
der Heiden et al., 2009). Thesemetabolic alterationsmay provide
substrates and energy necessary for cell growth, promote anti-
oxidant defense, and produce signals that alter gene expression
and drive pro-oncogenic signaling pathways. These discoveries
are revealing new approaches to cancer therapy that target
metabolic functions important for tumorigenesis. One underex-
plored area within the sphere of metabolic alterations in cancer
is represented by the tumor type oncocytoma.
Oncocytomas are rare, predominantly benign neoplasms
mostly of epithelia that have inactivating mutations in mitochon-
drial genome-encoded enzymes or control regions that cause
respiration defects. Oncocytomas are also characterized by
the dramatic accumulation of these defective mitochondria
(Gasparre et al., 2011). Whether the mitochondrial impairments
are functionally neutral, promote tumor growth as Warburg envi-
sioned, or to the contrary are a liability is unknown. It is also un-
clear why defective mitochondria accumulate and if this plays
any role in disease. Oncocytomasmay represent an evolutionary
dead end or an intermediate that progresses to more aggressive
cancer. Identifying mechanisms that restrict some tumors such
as these to benign disease can inform novel approaches to can-
cer therapy.
Mitochondria are essential for eukaryotic cell function. Cells
contain hundreds of mitochondria, with their numbers controlled
by both a transcription program of biogenesis (Wallace, 2012)
and removal of defective mitochondria through mitophagy, a
selective form of autophagy (Youle and Narendra, 2011). Thus,
the presence of tumor cells with the accumulation of defective
mitochondria suggests increased biogenesis, possibly as a
compensatory mechanism (Simonnet et al., 2003), or an under-
lying defect in removal by mitophagy (Guo et al., 2013b). As
autophagy deficiency in genetically engineered mouse models
for KrasG12D- and BRAFV600E-driven lung cancers convertsports 13, 1895–1908, December 1, 2015 ª2015 The Authors 1895
Figure 1. Identification of Two Main Subtypes of Renal Oncocytoma
(A) Copy-number variations in renal oncocytomas in comparison to eosinophilic ChRCC (eosinophilic ChRCC sequencing data were downloaded from the TCGA
CGHub repository [https://cghub.ucsc.edu/]) (Davis et al., 2014). Blue corresponds to loss of one copy, red corresponds to a gain, and gray on chromosome Y
indicates a female.
(B) Somatic mutations in renal oncocytomas in comparison to ChRCC (ChRCC sequencing data were downloaded from the TCGA CGHub repository [https://
cghub.ucsc.edu/]) (Davis et al., 2014). Only SNVs commonbetween oncocytoma andChRCCare shown; the complete list of detected somatic SNVs and indels is
reported in Tables S2 and S3.
(C) Expression levels of key genes from the transcriptome analysis. Each bar represents log2-transformed transcript abundance. Error bars show SEs.
(D) Principal component analysis (PCA) of gene expression identifies two subtypes of oncocytoma. The first principal component (PC1) separates tumor and
normal samples; the second principal component (PC2) separates oncocytomas into two subtypes.
(legend continued on next page)
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carcinomas to more benign oncocytomas, defects in mitochon-
drial removal may underlie the oncocytoma phenotype and pro-
duce benign instead of malignant disease (Guo et al., 2013a;
Karsli-Uzunbas et al., 2014; Strohecker et al., 2013). This also
suggests that autophagy and mitochondrial quality control are
important for promoting tumorigenesis (Guo et al., 2013b).
To address the cause and role of oncocytomas in the spec-
trum of cancer, we sequenced the exome and transcriptome of
the most common oncocytoma, those that arise in the kidney
(Linehan and Ricketts, 2013). We identified two major subtypes,
one without (type 1) and the other with (type 2) recurrent whole-
chromosome losses that contain few other mutations. Both
subtypes had recurrent inactivating mutations in nuclear- and
mitochondria-encoded proteins critical for respiration and dis-
played activation of AMPK and p53. Recurrent CCND1 chromo-
somal rearrangement and overexpression was a likely cancer
driver mutation in type 1. Both subtypes had evidence of defec-
tive autophagy attributed to metabolic-deficiency-induced Golgi
disassembly and lysosome dysfunction that blocked LAMP-2
trafficking and lysosomal protease activation. Pharmacologic
inhibition of mitochondrial complex I with metformin to repli-
cate mitochondrial dysfunction in oncocytomas caused AMPK
activation and Golgi disassembly and blocked LAMP-2 traf-
ficking and autophagy. Thus, mitochondrial respiration defects
that arise early in renal tumorigenesis trigger a metabolic check-
point, trafficking and lysosome defects, and failure of mitochon-
drial quality control, activating p53 and AMPK as a barrier to
tumor progression. Moreover, the similarities in the mutational
landscape and transcriptome suggest that type 2 oncocytoma
and eosinophilic subtype of chromophobe renal cell carcinoma
(ChRCC) are closely related, with ChRCC having acquired addi-
tional driver mutations in p53 and PTEN and further genetic
instability. Thus, treatment of type 2 oncocytomas requires
more consideration.
GenomicAnalysis Indicates TwoMain Subtypes of Renal
Oncocytoma
Whole-exome sequencing of 12 renal oncocytomas andmatched
adjacent normal tissue and RNA sequencing of 9 of these pairs
were performed. Copy-number variation (CNV) analysis from
exome sequencing indicates that tumors are clonal, with two
distinct subtypes based on the pattern of aneuploidy. One tumor
was an outlier that was excluded from further analysis. Type 1
is diploid and type 2 is hypodiploid with loss of chromosome 1,
X or Y, and/or 14 and 21 (Figures 1A and S1A; Table S1A). Type
1 shows no sex bias, but type 2 has male predominance (five
male/one female), suggesting strong selection for loss of the
Y chromosome. The one type 2 tumor arising in a female has
lost one X chromosome (Figure 1A). Strong selection for loss
of Y in males or X in females suggests possible involvement of
gene loss on the pseudoautosomal region (PAR).
Few and no recurrent single-nucleotide variants (SNVs) (162
nonsynonymous SNVs in 11 tumors; Tables S1B and S2) or in-(E) Type 1 and type 2 oncocytomas have distinct histology, with type 2 having a la
(F) Gene expression similarities between oncocytoma and ChRCC. PCA of gene
identify the three RCC subtypes as separate clusters with the corresponding ma
demonstrating similarities in gene expression patterns.
Cell Resertions/deletions were detected (Table S3). There were no mu-
tations in common cancer-causing genes (p53, PTEN) with the
exception of one tumor with anMLL3mutation (Figure 1B). Three
tumors have mutations in nuclear-encoded mitochondrial genes
NDUFV1,UQCRC2 (type 1), and SLC25A5 (ANT2) (type 2). ANT2
is located on the X chromosome, and this ANT2 mutant tumor
likely has a loss-of-function mutation as it has a frameshift muta-
tion with X chromosome loss (Figure 1B; Table S3). Mutations in
FLCN, VHL, FH, SDHB, SDHC, or SDHD, known drivers in other
renal cell carcinomas (RCCs), were not detected. Despite loss of
chromosome 1 in type 2, expression levels of FH, SDHB, and
SDHC located on chromosome 1 were not affected (Figure 1C).
The nuclear genome mutation spectrum observed in onco-
cytomas was C > A (132), C > G (98), C > T (329), T > A (64),
T > C (147), and T > G (97). The analysis showed transition to
transversion ratio (Ts/Tv) of 1.22 in somatic mutations in contrast
to 2.33 for germline mutations (found in dbSNP) consistent with
expected values (Ebersberger et al., 2002). The comparison
displayed strong enrichment for transversion mutations among
somatic mutations, suggesting reactive oxygen species (ROS)
exposure at some point in oncocytoma evolution.
Oncocytomas have mitochondrial genome mutations respon-
sible for respiration defects (Gasparre et al., 2007; Mayr et al.,
2008; Simonnet et al., 2003), with all oncocytomas examined
here having mutations, and mutations in MT-COX1, MT-COX2,
MT-COX3, MT-ND4, MT-ND5, and MT-CYTB found in three or
more tumors (Figures 1B and S1B; Table S4). Thus, the distin-
guishing feature of both subtypes of renal oncocytoma is recur-
rent inactivating mutations in mitochondrial genes encoded by
both the nuclear or mitochondrial genomes.
The mitochondrial point mutation spectrum for oncocytomas
was C > T (46) and A > G (10) on the heavy strand and C > T
(10) and A > G (3) on the light strand. The only other point muta-
tions detected were C > A (7) on the light strand. The dominance
and strand bias of C > T and A >Gmutations on the heavy strand
are consistent with findings from other human cancers and
postulated to result from mitochondrial DNA replication errors
(Ju et al., 2014). In contrast, the C > A mutations are consistent
with damage by ROS (Thilly, 2003), which were elevated (9%)
compared to other cancers (4%), (Ju et al., 2014). While the
majority of oncocytoma mitochondrial mutations showed the
signature of DNA replication error indicating that DNA replication
errors are the dominant source of mutations, most of the patho-
genic mutations with high allelic frequencies (>75%) are indels
and occure in the complex I subunits. In summary, 7 out of 11 on-
cocytomas have a pathogenic mitochondrial DNA mutation fre-
quency greater than 75% (Table S4).
The gene expression pattern also represents type 1 and 2
oncocytomas as distinct groups and indicates that the matched
normal adjacent tissue (NAT) from sample 5 is likely contami-
natedwith tumor (Figures S1C and S1D, A). Principle component
analysis (PCA) shows type 1 and 2 grouping separately with type
2 forming a tighter cluster showing greater similarity (Figure 1D).rger volume of eosinophilic cytoplasm relative to the nucleus. Error bar, 50 mm.
expression for oncocytoma, ChRCC, clear cell RCC, and papillary cell RCC
tched normal samples forming one cluster. Oncocytomas cluster with ChRCC
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Figure 2. Chromosome Rearrangements and Overexpression of CCND1 in Type 1 and p53 Activation in Type 1 and 2 Oncocytomas
(A) Overexpression of a single allele of CCND1. The RNA-sequencing coverage tracks for four tumors (T2, T6, T7, and T9) and matched normal samples (N2, N6,
N7, and N9) are shown in gray. The numbers in brackets display the coverage for this region and reflect the level of the gene expression, showing that CCND1 is
over 10-fold higher in tumors. SNPs present in the exons ofCCND1 are shown as colored bars. Some of the SNPs are heterozygous and are indicated by the two-
color bars showing the relative expression of the two alleles. The appearance of homozygous SNPs in tumor where the same SNPs appear heterozygous in the
matched normal sample, as in T2 versus N2, is a result of the overexpression of a single allele of CCND1.
(B) Western blot showing elevated CCND1 protein expression in tumors. The asterisks marks sample 5, which has normal (N) tissue mixed with oncocytoma (O)
tissue. Multiple bands represent different phosphorylated forms of CCND1.
(C) Representative fluorescence images of CCND1 FISH show rearrangement in type 1 (sample 2), but not type 2 (sample 3), tumors. White arrowheads show
segregation of CCND1 probe.
(D) Karyotype of renal oncocytomas shows chromosomal rearrangement including translocations, inversions, and deletions near CCND1 in type 1 and loss of
chromosome 1 and Y in type 2.
(E) Summary of genetic alterations in all 39 oncocytoma samples.
(legend continued on next page)
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The separate groups persist using only gene expression from
diploid chromosomes from types 1 and 2 (Figure S1D, B and
C). Both types are distinct from normal controls (Figures 1D
and S1C). Type 1 and 2 are distinguished histologically, with
type 2 having a more expansive eosinophilic cytoplasm (Figures
1E and S2), suggesting greater accumulation of defective mito-
chondria, thought to be a main contributing factor to the histo-
logical appearance of these tumors.
Type 2 Oncocytoma May Be the Precursor of
Eosinophilic ChRCC
The relationship between oncocytomas and other renal tumors
is not currently known. Thus, we compared the genomic and
transcriptomic signature of oncocytomas with RCC subtypes.
The pattern of gene expression in oncocytoma was clearly
distinct from clear cell and papillary cell RCC (Figure 1F), consis-
tent with the vastly different mutational landscape of these
tumors (Gao et al., 2013; Varela et al., 2011). In contrast, ChRCC
has some histologic similarities and common biomarkers with
oncocytoma, and distinguishing these tumor types is important,
as ChRCC is a more aggressive disease with higher risk of
metastasis (Ng et al., 2014).
There are two types of ChRCC, classic and eosinophilic, with
the eosinophilic subtype possessing some similarities with onco-
cytoma (Davis et al., 2014). The global gene expression pattern
of both oncocytoma and ChRCC are similar (Figure 1F), and
both have a gene expression signature of distal tubule, suggest-
ing that they originate from a common cell type (Figure S1E).
Eosinophilic ChRCC has two subgroups: one is chromosomally
diploid like type 1 but without rearrangement or overexpression
of CCND1, and the other has a pattern of chromosome loss
similar to type 2 with loss of chromosomes 1, X, or Y, but with
further losses including 2, 6, 10, 13, and 17 (Figures 1A and
1B) (Davis et al., 2014). Like type 2, eosinophilic ChRCC also
has a sex bias (15 male/4 female) whereas classic ChRCC has
no gender bias (24 male/23 female) (Figure 1A; Table S5). The
main nuclear genomic difference between oncocytomas and
ChRCC are mutations in p53 and PTEN in ChRCC (Figure 1B).
TERT promoter mutations and upregulation of telomerase
reverse transcriptase (TERT) expression occur in 10%of ChRCC
(Davis et al., 2014), and both oncocytoma subtypes lacked
TERT expression (Figure 1C), indicating the absence of this
driver mutation. The similarities in gene expression, aneuploidy
pattern, and histology suggest type 2 may be closely related to
eosinophilic ChRCC. One possibility is that ChRCC may have
acquired additional mutations in TP53, PTEN, or TERT, leading
to further genomic instability and a less indolent natural history.
Alternatively, there could be a single cell type precursor for
both type 2 oncocytoma and ChRCC, where chromosome 1 is
lost followed by either pathogenic mitochondrial genome or
p53 mutations, directing fate to either oncocytoma or ChRCC.
This, however, does not account for the common mitochondrial(F) Oncocytomas have a gene expression signature similar to ChRCCwithout p53
gene expression values. The correlation is calculated for the set of genes (Table
mutation in p53.
(G) Western blot for p53 showing induction in oncocytomas with quantitation rel
Cell Remutations in type 1 and 2 oncocytoma without chromosome 1
loss in type 1.
In contrast to the increased nuclear genomic mutation burden
in ChRCC compared to oncocytoma, there was less mutational
burden of the mitochondrial genome in ChRCC compared to on-
cocytoma (p < 0.0001) (Figure 1B) (Davis et al., 2014). Hetero-
plasmy may be a prerequisite to selection for a less defective
pool of mitochondria during progression of benign type 2 to a
more malignant ChRCC.
Recurrent CCND1 Rearrangement and Amplification in
Type 1 Oncocytomas
Four of the five type 1 oncocytomas had high expression of
CCND1 in comparison to type 2 and NAT (Figure 1C). CCND1
encodes the cell-cycle regulator and oncoprotein CyclinD1. All
three tumors exhibit monoallelic expression of CCND1 consis-
tent with chromosomal rearrangement that led to aberrant high
expression of one CCND1 allele (Figure 2A) consistent with pre-
vious observations (Sukov et al., 2009). Western blot shows high
CyclinD1 protein expression in some tumors with high mRNA
expression (Figure 2B). CyclinD1 expression is also elevated in
some of the type 2 tumors, reflecting non-transcriptional mech-
anisms for CyclinD1 activation (Figure 2B).
Fluorescence in situ hybridization (FISH) analysis of three each
of type 1 and 2 oncocytomas confirmed translocation of 11q13
at the CCND1 locus in type 1 and not in type 2 (Figure 2C). Cyto-
genetic analysis of 28 additional renal oncocytomas showed
eight tumors with translocations, inversions, or deletions near
CCND1 (11q13) but an otherwise chromosomally intact genome
(Figure 2D). These findings are consistent with the presence of
two mutually exclusive categories of oncocytoma: type 1 with
CCND1 rearrangement and no other gross chromosomal losses,
and type 2with chromosome 1 loss. Of the 28 oncocytomas, two
were chromosomally stable, harboring a translocation between
chromosomes 6 and 9 of unknown significance (Figure 2D)
(Hudacko et al., 2011). Five others had unique chromosome re-
arrangements and CNVs, suggesting low-level diversity of this
tumor type (Figures 2D and 2E). The expanded characterization
of 39 oncocytomas confirmed the association of type 1 with
CCND1 rearrangements (12/13) and type 2 with chromosome
1 loss (19/19), sex chromosome loss (11/19), and male bias
(12/19 male, 7/19 female) (Figure 2E). No aberrant high expres-
sion of CCND1 was detected in chromosomally stable ChRCC
(six tumors) so there is no evidence that type 1 progresses to a
subset of ChRCC that also lacks chromosomal losses. Since
translocation or rearrangement of CCND1 and overexpression
of CyclinD1 is a well-known oncogenic driver, it is likely a driver
mutation in type 1 oncocytomas.
p53 Is a Barrier to Oncocytoma Progression
p53 is mutated in 22 out of 66 (33%) ChRCC tumors (Davis et al.,
2014) and not in oncocytoma (Figure 1B). We found a set ofmutation as shown by correlation heat map between oncocytoma and ChRCC
S6), which are differentially expressed between ChRCCs with and without a
ative to ACTIN.
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Figure 3. Oncocytomas Show a Gene Expression Signature of Oxidative Metabolism and Mitochondrial and Energetic Defects
(A) Oncocytomas have increased mitochondrial DNA copy number. p value was calculated for a one-tailed t test.
(B–D) Canonical pathway analysis. Each graph represents the top 15 canonical pathways enriched for the corresponding gene set (http://www.ingenuity.com/).
Numbers on top of the bars indicate the number of genes in the pathway. Differential expression analysis of type 2 versus type 1 identifies 50 genes with
FDR-corrected p value < 0.05.
(B) Pathway analysis of a set of 1,042 genes differentially expressed between tumor and normal samples. The set of genes was selected based on the
FDR-corrected p value < 0.05. Red corresponds to genes that are upregulated in oncocytomas, and green corresponds to genes downregulated in oncocytomas.
(C) Pathway analysis of a set of 457 genes that are upregulated in oncocytomas compared to normal samples. The set of genes was selected based on the
FDR-corrected p value < 0.05. Red arrowhead marks AMPK signaling.
(D) Pathway analysis of a set of 500 genes differentially expressed between type 1 and type 2 oncocytoma. The set of genes was selected based on the lowest
p values. Red corresponds to genes upregulated in type 2. Red arrowheads mark AMPK and p53 signaling.
(legend continued on next page)
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genes differentially expressed between ChRCCwith and without
p53mutation (Table S6) and oncocytomas have the gene signa-
ture more similar to ChRCC without p53 mutation (Figure 2F).
This finding is consistent with changes in gene expression linked
to p53 mutational status in both ChRCC and oncocytomas.
p53 protein is stabilized as a barrier to tumorigenesis by
stress, oncogene activation including CCND1 amplification,
and genome damage. To test if p53 was activated in benign on-
cocytomas explaining its mutation upon progression to ChRCC
in type 2, we examined p53 levels. In comparison to NAT, wild-
type p53 protein was induced in most oncocytomas indepen-
dent of subtype, suggesting that p53 activation in oncocytomas
may contribute to their slow growth and benign characteristics
(Figure 2G).
Type 1 and 2 Oncocytomas Display Mitochondrial
Defects and Metabolic Stress
Since metabolic stress, triggered by mitochondrial defects, is a
potential cause of p53 activation in oncocytomas, we assessed
mitochondrial genome copy number, gene expression signa-
ture, mitochondrial complex protein expression, and metabolic
signaling. Both type 1 and 2 have elevated mitochondrial
genome copy number relative to NAT, with type 2 being greater,
suggesting increased mitochondrial accumulation (Figure 3A;
Table S7).
Pathway analysis of the transcriptome indicated that in com-
parison to NAT, oncocytomas have a predominance of downre-
gulated genes that are represented inmetabolic and degradative
pathways (Figure 3B; Tables S8 and S9). Mitochondrial accumu-
lation in oncocytomas may be due to compensatory increased
biogenesis or decreased clearance by autophagy, concepts
that are not mutually exclusive. Indeed, PPARGC1a expression
is induced several fold in oncocytomas compared with NAT
(Table S9), indicating activation of mitochondrial biogenesis.
Pathway analysis of genes upregulated in oncocytomas identi-
fied AMPK, creatine-phosphate biosynthesis, and ketolysis
pathways suggestive of energy crisis (Figure 3C; Table S9). On-
cocytomas have high expression of genes encoding the TCA cy-
cle and other mitochondria-expressed gene products involved in
respiration (Figure 3C; Table S10). Comparison of differential
gene expression between types 1 and 2 identified metabolic
and cancer pathways such as AMPK and p53 (Figure 3D; Tables
S11 and S12). Both type 1 and type 2 oncocytomas have AMPK
pathway upregulated compared to NAT, with upregulation more
pronounced in type 1. Type 1 has 3.4-, 6.7-, 2.4-, and 4-fold
higher levels of PRKAB2, PRKAG2, ACACA (ACC1), and ACACB
(ACC2), whereas type 2 has 8-, 2.2-, and 3.3-fold higher levels
of PRKAG2, ACACA, and ACACB, respectively. The mitochon-
drial accumulation and genome mutations, oxidative meta-
bolism gene expression signature, and patterns of chromosome
loss suggest similarities between oncocytomas and eosinophilic(E) Oncocytomas show upregulation of a gene expression signature for mitochon
encoded genes as for ChRCC (Davis et al., 2014) for ease of comparison. Ye
mutations. Star indicates somatic mutations in nuclear-encoded genes.
(F) Deregulation of mitochondrial protein expression in oncocytomas determined
(G) Oncocytomas have loss of mTOR as indicated by reduction of P-S6 (Ser 23
(a-subunit, Thr 172) in western blots.
Cell ReChRCC (Figure 3E) (Davis et al., 2014). This may reflect
an increased number of mitochondria and not necessarily
increased mitochondrial metabolism.
Increased mitochondrial genome copy number was reflected
in high cytochrome c levels in oncocytomas relative to NAT in
all tumors with the exception of sample 5, where normal tissue
was contaminated with tumor (Figure 3F). Mitochondrial genome
mutations resulting in defects in complex I of the electron trans-
port chain (ETC) are common in oncocytomas (Figures 1B and
S1B) (Gasparre et al., 2007; Mayr et al., 2008; Simonnet et al.,
2003). Low or undetectable levels of the subunit NDUFS1 (com-
plex I), UQCRC2 (complex III), and MT-COX2 (complex IV) were
observed in a subset of oncocytomas indicative of impairment in
mitochondrial respiration atmultiple points in the ETC (Figure 3F).
Compared to NAT, ANT2, and SLC25A6 (ANT3), protein expres-
sion levels were low or undetectable in type 2 in contrast to the
increased mitochondrial mass (Figure 3F). ANT3 is on the PAR
and had a reduced mRNA expression (log2 fold change =
0.9, uncorrected p = 0.04) associated with loss of the Y or X
chromosome and correspondingly reduced protein expression
(Figure 3F). Tumor 8 had no detectable ANT2, likely due to a
frameshift mutation and X chromosome loss containing the other
allele (Figures 1B and 3F). Interestingly, mutations in ANT2 also
occur in ChRCC (Figure 1B). ANT2 and ANT3 modulate the
mitochondrial permeability transition pore, and their deficiency
impairs mitochondrial function (Kokoszka et al., 2004). These
findings are consistent with unifying defects in mitochondrial
function in oncocytomas.
To examine the potential manifestation of mitochondrial
metabolic defects on oncocytoma, we assessed the activity
of the nutrient sensor and master regulator of cell growth, the
mammalian target of rapamycin (mTOR), and the metabolic
stress response regulator AMPK. Both subtypes had reduced
phospho(P)-S6, indicating loss of mTOR activity, and increased
phospho(P)-AMPK (Thr 172) (Figures 3G and S1F), indicating
activation of AMPK signaling, consistent with upregulation of
the gene expression signature (Figure 3C, arrow). These findings
reflect metabolic and growth impairment consistent with defec-
tive mitochondrial function in oncocytomas.
Oncocytomas Manifest Phenotypes of Defective
Autophagy
To test if autophagy defects underlie the accumulation of defec-
tive mitochondria in oncocytomas, we examined the levels of
autophagy substrates that accumulate with autophagy inactiva-
tion. Oncocytomas show accumulation of mitochondria that are
normally degraded by autophagy as determined by immuno-
histochemistry (IHC) and western blotting for the mitochon-
drial proteins TOM20 and cytochrome c (Figures 4A and 4B).
Levels of the essential autophagy regulator BECLIN1 were
reduced (Figures 4B and S2), and puncta of LC3 indicative ofdrial respiration. Red and blue correspond to up- or downregulation of nuclear-
llow and gray correspond to mitochondrial genes with and without somatic
by western blots. The asterisk marks sample 5 with mixed normal and tumor.
5/236) and induction of AMPK signaling as indicated by induction of P-AMPK
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Figure 4. Oncocytomas Lack Autophagosomes, Accumulate Autophagy Substrates and Dysfunctional Mitochondria, and Are Primed for
Mitophagy
(A) Human oncocytomas accumulate mitochondria (TOM20) and p62 (autophagy substrate) and lack LC3 puncta (autophagosomes) indicative of autophagy
inactivation. Representative IHC for each of the two subtypes with all in Figure S2.
(B) Western blots of indicated mitochondrial and autophagy proteins in normal tissues and oncocytomas. Quantitation of LC3-I/II and p62 levels is shown below.
(C) Oncocytomas have evidence for activation of the fission and the PINK1/PARKIN machinery. Western blots of normal and oncocytoma tissues for indicated
proteins. FL, full length; DMTS, without mitochondrial translocation sequence.
(legend continued on next page)
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autophagosomes were present in NAT and absent in oncocyto-
mas (Figure 4A). Consistent with the absence of LC3 puncta and
autophagy, oncocytomas had higher levels of the unprocessed
form of LC3 (LC3-I) and lower levels of the processed, autopha-
gosome-associated form of LC3 (LC3-II) than NAT as indicated
by western blotting and LC3I/II ratios (Figure 4B). The absence
of LC3-II and autophagosomes and the accumulation of LC3-I
is a characteristic of genetic ablation of an essential auto-
phagy gene in mice (Karsli-Uzunbas et al., 2014). Oncocytomas
also displayed high levels of the autophagy substrate p62 that
accumulates in autophagy-defective cells and tissues (Figures
4A and 4B).
Mitophagy Is Primed, but Not Executed, in Oncocytomas
Since oncocytomas accumulate defective mitochondria, we
examined oncocytomas for evidence of mitophagy dysfunc-
tion. Mitochondria undergo fission in response to stress to
allow their segregation and elimination by mitophagy. Fission
is induced when the protease OMA1 cleaves the dynamin-
related GTPase OPA1 (McBride and Soubannier, 2010). Mi-
tophagy is subsequently activated by loss of mitochondrial
membrane potential that prevents cleavage and inactivation
of the kinase PTEN-induced putative kinase 1 (PINK1), which
recruits the E3 ligase PARKIN to mitochondria (Youle and
Narendra, 2011). PARKIN then adds ubiquitin chains to
mitochondrial outer membrane proteins to signal recruitment
of autophagy adaptors such as p62, which interact with
LC3-II in autophagosome membranes, allowing their engulf-
ment within autophagosomes.
In normal conditions, OMA1 is cleaved and OPA1 is not, allow-
ing fusion and preventing fission and mitophagy. This was the
case in NAT, where cleaved OMA1 (40 kDa) and less cleaved
OPA1 (S-form) were apparent (Figure 4C). In contrast, oncocyto-
mas have uncleaved OMA1 (60 kDa) and accumulation of
cleaved OPA1 (S-form) consistent with activation of fission.
Since LC3-II-positive autophagosomes were not detected in
oncocytomas (Figures 4A and 4B), this suggests that the initial
steps of mitochondrial fission are initiated but the process of
autophagosome sequestration is not. Oncocytomas have un-
cleaved PINK1 (FL-PINK1) and accumulation of PARKIN, consis-
tent with priming of mitophagy without autophagosome forma-
tion (Figure 4C). PINK1 is cleaved by PARL and further cleaved
to the p45kDa fragment to inactivate fission and mitophagy
when mitochondria are healthy. Importantly, normal tissue but
not oncocytomas have the p45kDa cleaved PINK1, consistent
with inactivation of PINK1 and priming of mitophagy (Figure 4C).
Interestingly, cells with pathogenicmitochondrial DNAmutations
are defective for mitochondrial membrane fusion (Mishra et al.,
2014), consistent with activation of the fission machinery and
the PINK1/PARKIN system shown here in oncocytomas (Fig-
ure 4C). Thus, upstream signaling of mitophagy at mitochondria(D) Primary cultures of oncocytoma cells display autophagy substrate accumu
oncocytoma cells (O159/O144) accumulate LC3 and p62 aggregates, mitochond
(E) Primary cultures of oncocytoma cells (0159/O144) show accumulation of dys
icantly lower relative membrane potential than normal cell controls NK159 and N
(F) Primary oncocytoma cells (O159) have reduced OCR and increased ECAR wh
(N159).
Cell Reoccurs in oncocytomas, but sequestration is absent, suggesting
a block in autophagy.
Impaired Mitochondrial Respiration in Primary
Oncocytoma Cells
Attempts to generate cell lines from renal oncocytomas by
others and us have been unsuccessful. To address mitochon-
drial function, two pairs of normal adjacent kidney (NK159/
N144) and oncocytoma-derived (O159/O144) primary cell cul-
tures were examined. Primary oncocytoma cells remain viable
in short-term culture (<1 week) without undergoing cell division,
permitting limited analysis. In contrast to NK159 and N144, O159
and O144 primary cultures were composed of large cells with
LC3 and p62 aggregates and increased mitochondria, glycogen,
and lipids indicative of defective autophagy (Figure 4D). Even
though primary oncocytoma cells had severalfold greater mito-
chondrial mass, relative mitochondrial membrane potential
was significantly lower when compared to normal cells, consis-
tent with ETC defects (Figure 4E). One of the primary cultures
(O159) provided sufficient material for determination of the oxy-
gen consumption rate (OCR) and extracellular acidification rate
(ECAR). Compared to normal cells, O159 cells were defective
for respiration and more glycolytic, consistent with pathogenic
mitochondrial genome mutations (Figures 4F and S1B).
Oncocytomas Display LAMP-2 Trafficking, Golgi, and
Lysosome Defects
Autophagy delivers cargo to lysosomes for degradation, and
interference with lysosome function and cargo degradation feeds
back to inhibit autophagy (Tanaka et al., 2000). Moreover, muta-
tions in themajorandessential lysosome transmembranecompo-
nent lysosome-associated membrane protein-2 (LAMP-2) cause
lysosomal storage disease and interfere with autophagy (Eskeli-
nen, 2006). To test if lysosome defects in oncocytomas interfere
with autophagy, lysosome numbers and localization were exam-
ined by monitoring LAMP-2. LAMP-2-positive vesicle distribution
in types 1 and 2 was distinct from NAT (Figure 5A). In contrast,
and suggestive of lysosome abnormality, localization of LAMP-
2-positive vesicles was perinuclear in type 1 and peripheral in
type 2 (Figure 5A).
LAMP-2 is synthesized and heavily polylactosamine glycosy-
lated in the Golgi apparatus prior to transit to lysosomes, which
serves to protect the protein from proteolysis in the lysosome
lumen where most of the polypeptide resides. Oncocytomas
have enhanced glycosylation of LAMP-2 compared to NAT as
indicated by its higher molecular weight (Figure 5B). Increased
glycosylation of LAMP-2 occurs when it is retained in the Golgi,
where this post-translational modification takes place (Nabi and
Rodriguez-Boulan, 1993). In contrast to perinuclear stacks of
Golgi in NAT, oncocytomas displayed disrupted Golgi organiza-
tion with LAMP-2 co-localization (Figures 5A and 5C), consistentlation. In contrast to primary cells derived from NAT (NK159/N144), primary
ria, glycogen, and lipids, characteristics of autophagy impairment.
functional mitochondria with several fold more mitochondrial mass but signif-
144.
en provided a fermentable carbon source in comparison to normal control cells
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Figure 5. Golgi Disassembly, Altered LAMP-2, and Defective
Cathepsin Activation in Oncocytomas
(A) Golgi disassembly and altered LAMP-2 localization in human oncocyto-
mas. Representative IHC for each subtype with all shown in Figure S2.
(B) Western blots showing enhanced LAMP-2 glycosylation (increased
molecular weight) in human oncocytomas. Oncocytomas have defective
CTS-B and -L activation. Low molecular weight, cleaved, activated forms of
cathepsins predominate in normal tissue. Pro, proenzyme; Int, intermediate.
(C) Golgi disassembly and LAMP-2 co-localization in human oncocy-
tomas. Representative fluorescence images of each subtype stained for Golgi
(GM130), LAMP-2, and nuclei (DAPI). The fluorescence images of all are shown
in Figure S2.
1904 Cell Reports 13, 1895–1908, December 1, 2015 ª2015 The Autwith Golgi disassembly and LAMP-2 retention and enhanced
glycosylation (Figures 5B and 5C).
The major lysosomal proteases, cathepsins (CTSs), are also
processed in the Golgi and cleaved and activated to mature
forms upon reaching the acidic environment of lysosomes (Ishi-
doh and Kominami, 2002). In contrast to NAT, most oncocyto-
mas had predominantly inactive CTS-B and -L and lacked the
cleaved, active forms, indicative of defective trafficking and lyso-
some function (Figure 5B). CTS-B and -L are cysteine proteases
involved in lysosomal protein turnover, and failure to activate
them is consistent with the accumulation of autophagic sub-
strates in oncocytomas. These findings suggested that mito-
chondrial defects and energy crisis in oncocytomas produce a
general disruption of Golgi-lysosome protein trafficking that
impairs autophagy.
The Golgi is a highly structurally organized organelle essential
for protein sorting, trafficking, and post-translational modifica-
tion. The Golgi undergoes disassembly at mitosis for proper par-
titioning in daughter cells and in response to metabolic stress to
conserve energy (Mao et al., 2013). To test if metabolic stress
triggers Golgi disassembly and enhances LAMP-2 glycosylation
that is alleviated by autophagy, isogenic tumor cells wild-type or
null for the essential autophagy gene ATG7 (Guo et al., 2013a)
were starved and Golgi and LAMP-2 localization and glycosyla-
tion were examined. Wild-type cells displayed no changes in
LAMP-2 glycosylation but had increased P-AMPK, inhibition of
P-S6, perinuclear Golgi with distinct LAMP-2 localization, and
only modest Golgi disruption with prolonged starvation (Figures
6A and 6B). Autophagy-deficient ATG7 null cells, however,
showed Golgi disruption and enhanced LAMP-2 glycosylation
even under normal growth conditions, which was increased by
starvation (Figures 6A and 6B). LAMP-2 co-localized with the
Golgi in the starved ATG7-deficient cells, consistent with Golgi
retention (Figure 6B). Thus, metabolic crisis induced by either
starvation or autophagy deficiency disrupts the Golgi and alters
LAMP-2 glycosylation.
Complex I Inhibition and Golgi Disassembly Block
Autophagy
Metabolic stress and AMPK activation triggers Golgi disas-
sembly by phosphorylation of Golgi-specific brefeldin A resis-
tance factor 1 (GBF1), a guanine nucleotide exchange factor
(GEF) for Arf-GTPases. Phosphorylation of GBF1 disassociates
GBF1 from the Golgi membrane, producing Golgi fragmentation
(Miyamoto et al., 2008). To test the hypothesis that mitochon-
drial mutations impairing complex I in oncocytomas produce
metabolic crisis that disrupts Golgi function, thereby inhibiting
autophagy, we examined the cellular response to the complex
I inhibitor metformin (Bridges et al., 2014). Metformin potently
induced AMPK activation (increased P-AMPK), inhibited mTOR
(reduced P-S6), disrupted the Golgi, produced Golgi-LAMP-2
co-localization, and enhanced LAMP-2 glycosylation (Figure 6C).
Importantly, metformin reduced autophagic flux as measured by
inhibition of LC3-I to -II processing and LC3 puncta in the pres-
ence of BA1 (Figure 6D). The other complex I inhibitors phenfor-
min and rotenone acted similarly (Figure 6E). Treatment with the
AMPK activator AICAR confirmed that these changes are AMPK
mediated (Figure 6E). Pharmacological disruption of the Golgihors
Figure 6. Sustained Metabolic Stress Induces AMPK Signaling, Golgi Disassembly, Golgi-LAMP-2 Co-localization, and LAMP-2 Hyper-
glycosylation and Inhibits Autophagy Flux
(A) Autophagy deficiency and starvation increase LAMP-2 glycosylation. Western blots of autophagy-competent and autophagy-deficient TDCLs following 0, 4,
and 8 hr of starvation (HBSS) for the indicated proteins. Starvation induces AMPK signaling (increased P-AMPK) and reduces mTOR activity (decreased P-S6).
(B) Autophagy deficiency and starvation cause Golgi disassembly and LAMP-2 co-localization. Representative fluorescence images of autophagy-competent
and autophagy-deficient TDCLs stained for Golgi (GM130), LAMP-2, and DNA (nuclear DAPI).
(C) Metformin (Met) disrupts Golgi and causes LAMP-2 co-localization. Autophagy-competent TDCLs stained for Golgi (GM130), LAMP-2, and nuclei (DAPI)
following metformin treatment for the indicated times. White arrowheads show Golgi-LAMP2 co-localization. Bottom panel: western blots from samples.
(D) Metformin disrupts autophagic flux. Western blots of metformin-treated wild-type TDCLs for LC3 showing less LC3-II in BA1. Metformin disrupts autophagic
flux indicated by reduced puncta of endogenous LC3 with BA1 with quantitation.
(E) Phenformin (Phen), Rotenone (Rot), 5-aminoimidazole 4-carboxamide ribonucleotide (AICAR), and brefeldin A (Bref A) disrupt Golgi and cause Golgi-LAMP-2
co-localization and LAMP-2 hyper-glycosylation. Autophagy-competent TDCLs stained for Golgi (GM130) and LAMP-2 following Phen, Rot, AICAR or Bref A
treatment for indicated times. Nuclei (DAPI). Bottom panel: corresponding western blots.
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Figure 7. Model for Oncocytoma Genesis
Chronic mitochondrial metabolic defect causes
mitochondrial accumulation.with brefeldin A induced Golgi-LAMP2 co-localization and
LAMP-2 hyper-glycosylation (Figure 6E). Thus, mutational inac-
tivation of the mitochondrial ETC in oncocytomas is likely the
cause of AMPK activation and disruption of Golgi, autophagy,
and lysosome function.
DISCUSSION
Molecular characterization of benign renal oncocytomas re-
vealed two main subtypes that share recurrent inactivating
mutations in mitochondrial genes encoded by both nuclear
and mitochondrial genomes. Clonal expansion of somatic mito-
chondrial mutations in oncocytomas suggests that they are an
early event (Gasparre et al., 2008). This might indicate a causal
role for mitochondrial defects in tumor promotion as previously
suggested (Gasparre et al., 2011). The genomic analysis of renal
oncocytomas performed here was not able to resolve this
issue; however, alterations of the nuclear genome consistent
with oncogene activation and tumor suppressor gene inactiva-
tion were found in almost all cases.
Several issues we were able to address were the relationship
between oncocytomas and other renal tumors, the cause of the
metabolic defects, and the reasons for mitochondrial accumula-
tion. Diploid type 1 has chromosomal rearrangements and upre-
gulation of CCND1, a known oncogene. While type 2 lacked a
clear driver mutation, it was hypodiploid, which could be the
underlying basis for tumor formation, with the consistent loss
of chromosome 1 being the prime candidate for location of a tu-
mor suppressor gene. Loss of X or Y also suggests the presence
of a tumor suppressor on the PAR that escapes X inactiva-
tion. Despite differences at the genomic level, the two subtypes
were qualitatively similar in phenotype.
Our data suggest that oncocytomas have activated p53,
and type 2 may progress to more malignant eosinophilic
ChRCC upon acquiring p53, PTEN, and other mutations. Recent
sequencing findings also support similarities between renal
oncocytomas and ChRCC and the absence of p53 mutations1906 Cell Reports 13, 1895–1908, December 1, 2015 ª2015 The Authorsin oncocytomas (Durinck et al., 2015).
Autophagy deficiency in genetically engi-
neered mouse models causes energy
crisis, activates p53, and suppresses
tumor growth, effects lessened by p53
deficiency (Guo et al., 2013b). Analo-
gously, oncocytomas may represent
benign disease whose growth is limited
by metabolic crisis and activation of p53.
Subsequent mutation in p53 in type 2
may restore growth capacity and pro-
gression to eosinophilic ChRCC (Guo
et al., 2013a; Strohecker et al., 2013). It
is also worth noting that ChRCCs have
significantly fewer mitochondrial muta-tions than oncocytomas, suggesting that progression fromonco-
cytoma might be aided by heteroplasmy and the ability to partly
recover the functional pool of mitochondria (Ju et al., 2014).
This might be achieved by restoration of autophagy and lyso-
somal biogenesis by TFE3 or TFEB activation (Linehan and Rick-
etts, 2013). Alternatively, tumor cells depleted of mitochondrial
DNA recover respiration, ETC function, and tumor growth by
horizontal transfer of normal mitochondria from non-tumor to
tumor tissue (Tan et al., 2015). These findings point to the need
for tumors to preserve mitochondrial ETC function. In contrast,
type 1 may represent an evolutionary dead end, as these tumors
with CCND1 rearrangements are less susceptible to recurrence
(Sukov et al., 2009).
Recurrent pathogenic mitochondrial gene mutations en-
coded within the mitochondrial and nuclear genomes are the
likely cause of the respiration defects in oncocytomas, consis-
tent with and expanding on previous work. Inactivating muta-
tions are found in complex I, III, IV, and control regions, in
nuclear encoded NDUFA13, and now also in complex V,
ANT2, NDUFV1, and UQCRC2. Alterations in key mitochon-
drial components are associated with the accumulation of
defective mitochondria, suggesting a link between chronic
metabolic impairment and autophagy suppression. Indeed,
depletion of mitochondrial DNA and the resulting respiration
defect inactivates autophagy in budding yeast and mamma-
lian cells (Graef and Nunnari, 2011; Tan et al., 2015). In agree-
ment with these findings, the pathogenic mitochondrial muta-
tions and respiration defects in the oncocytomas reported
here similarly suppress autophagy with the resulting metabolic
insufficiency attributed to disruption of Golgi and lysosome
function (Figure 7).
A major consequence of compromised mitochondrial respi-
ration in oncocytomas is chronic metabolic deficiency exem-
plified by AMPK activation and loss of mTOR signaling.
This is also seen in genetically engineered mouse models for
cancer with autophagy inactivation (Guo et al., 2013b; Karsli-
Uzunbas et al., 2014) and in response to pharmacologic
inhibition of complex I (e.g., metformin) in cancer cells in vitro.
Normally, transient energy crisis and AMPK activation cause
Golgi disassembly to block trafficking and secretion that
is thought to conserve energy. In contrast, the dysfunctional
mitochondria in oncocytomas causes a chronic metabolic
defect, sustained energy crisis, AMPK activation, and disrup-
tion of Golgi and lysosome function essential for autophagic
cargo degradation (Figure 7). Importantly, inhibition of com-
plex I is sufficient to disrupt the Golgi, trafficking, and auto-
phagic flux. Thus, cancer cells need to sustain mitochondrial
respiration to prevent metabolic crisis that inhibits trafficking.
It is worth noting that PTEN and p53 mutations, which alleviate
AMPK activation, occur in ChRCC and may facilitate progres-
sion of type 2 tumors by restoring Golgi, autophagy, and lyso-
some function.
Oncocytic features are common to many different subsets
of renal tumors such as those with SDHB, SDHC, SDHD, and
FLCNmutations and in hybrid ChRCC tumors (Linehan andRick-
etts, 2013). This may be due to the occurrence of numerous
means to impair mitochondrial respiration, producing chronic
metabolic and trafficking defects, and the resulting mitochon-
drial accumulation as described here in oncocytomas. Metfor-
min and other means to inhibit mitochondrial function have
anti-cancer activity (Pollak, 2013; Viale et al., 2014; Weinberg
et al., 2010). Our findings suggest that this may be due in part
to chronic metabolic stress-induced trafficking defects, necessi-
tating the preservation of ETC function to overcome a metabolic
barrier to tumorigenesis.
EXPERIMENTAL PROCEDURES
Tumor Samples
Tumor and adjacent normal kidney tissues from ten sporadic oncocytomas at
MSKCC were collected. All patients had previously consented to a tissue
protocol. This study was preapproved by the institutional review board (IRB),
and all patients signed informed consent. All samples were reviewed by a dedi-
cated uropathologist. Paired fresh-frozen normal and primary tumor tissue
blocks were identified, marked, and macrodissected for maximal tumor den-
sity. The two tumor specimens with normal adjacent tissue from CINJ were
obtained from a de-identified tissue bank maintained at the Biospecimen
Repository Service under the auspices of an IRB-approved protocol. All spec-
imens were pre-existing and de-identified. Tissues for cytogenetics were
obtained by reviewing records to identify all cases of renal oncocytomas
and ChRCC for which cytogenetics was performed at Robert Wood Johnson
University Hospital in the past 10 years.
Whole-Exome and RNA-Sequencing Data Analysis
The Agilent SureSelect Human All Exon V5 Enrichment protocol was used for
exome capture. The exome was sequenced on Illumina HiSeq 2500, 2 3
100 bp paired-end reads to a minimum depth of 100 million reads per sample.
The reads were preprocessed with Picard to remove PCR duplicates and
aligned to the human reference genome (hg19) with Bowtie2. Somatic point
mutations and small indels were called with MuTect and GATK Somatic Indel
Detector algorithms. CNVs were detected with exomeCNV. Library prepara-
tion and RNA sequencing were carried out using the Illumina TruSeq RNA
Sample Prep Kit v2, according to the manufacturer’s protocol (Illumina), and
samples were sequenced on the Illumina HiSeq 2500 (2 3 100 bp paired-
end reads) to a minimum depth of 50 million reads per sample. Sequence
reads were mapped using TopHat2/Bowtie2 algorithm. Analysis of gene
expression was performed using Cufflinks and DESeq. The complete descrip-
tion of the sequencing and genomic analysis and all other methods can be
found in Supplemental Experimental Procedures.Cell ReACCESSION NUMBERS
The accession number for the sequencing data reported in this paper is SRA:
SRP051509.
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two figures, and twelve tables and can be found with this article online at
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